$211.43−1.79%Close 17 Nov 2026 · Market value $82.86B
In its results release of 6 Nov 2026 (Q3 FY2026), Moderna, Inc. gave 2 forecasts in figures, among them revenue growth of +15% to +25% for FY2026.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
Latest guidance given with Q3 FY2026 results, 6 Nov 2026
| Measure | Period | Guidance | As stated |
|---|
| Revenue growth | FY2026 | +15% to +25% | Increases 2026 expected revenue growth to 15%-25%, exceeding the previous expectation of up to 10% growth |
|---|
| Capital expenditures | FY2026 | About $200M | Capital Expenditures: Capital expenditures for 2026 are expected to be approximately $0.2 billion, improved from the previous expectation of $0.2 billion to $0.3 billion. |
|---|
Source: the company's earnings release.
Guidance against results last two years
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|
| Revenue growth | FY2026 | +15% to +25% | Given once | — | To come |
|---|
| Capital expenditures | FY2026 | About $200M | Lowered once | — | To come |
|---|
MRNA in the terminal
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.